UBS O'Connor’s 10x Genomics TXG Stock Holding History

UBS O'Connor’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21,644	Closed	-$1.09M	–	360
2019 Q3	$1.09M	Buy	+21,644	New	+$1.2M	0.03%	205

Other funds holding TXG

FCMI

Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

UBS O'Connor's TXG Position: Q4 2019 in Review

UBS O'Connor sold out of 10x Genomics (TXG) in Q4 2019, closing a stake of 21,644 shares — an estimated $1.09M sold.

UBS O'Connor first reported a position in TXG in Q3 2019 and held it in 1 quarter. The position peaked at $1.09M in Q3 2019. 85 funds tracked by Wall St. Rank hold TXG as of Q4 2019.

UBS O'Connor reported no remaining 10x Genomics position as of Q4 2019 after selling out during the quarter.
UBS O'Connor sold 21,644 10x Genomics shares in Q4 2019, an estimated $1.09M.
UBS O'Connor first reported a position in 10x Genomics in Q3 2019 and held it in 1 quarter.
UBS O'Connor's 10x Genomics position peaked at $1.09M in Q3 2019.
85 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2019.

Based on UBS O'Connor's 13F filing for Q4 2019, filed 14 Feb 2020.